THL Partners has announced a definitive agreement to acquire Headlands Research from KKR & Co. Inc. This strategic partnership aims to expand Headlands' network of clinical trial sites and accelerate clinical trial innovation. Founded by KKR in 2018, Headlands has grown significantly, focusing on inclusivity and operational excellence in clinical trials. THL will invest in Headlands through its Fund IX, with the transaction expected to close in 2025, pending customary closing conditions. Legal and financial advisors for the transaction included McDermott Will & Schulte, Paul, Weiss, Rifkind, Wharton & Garrison, Jefferies, Edgemont Partners, Houlihan Lokey, and Kirkland & Ellis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KKR & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814383571) on August 14, 2025, and is solely responsible for the information contained therein.